TABLE 2

Fitted Parameters of Patient Groups

			Meningioma			NET
Quantity	Organ	Parameter	Minimum	Maximum	Median	Minimum	Maximum	Median	Literature
Receptor concentration	Kidneys	R_K,0 (nmol·L⁻¹)	5.7	8.8	6.5	2.3	8.7	7.1	9 ± 8^*
	Spleen	R_S,0 (nmol·L⁻¹)	7.8	16.5	9.2	3.9	18	8.7	30 ± 26^*
	Liver	R_L,0 (nmol·L⁻¹)	0.86	2.5	1.1	0.63	2.1	1.2	2 ± 1^*
	Rest	R_REST,0 (nmol·L⁻¹)	0.39	0.94	0.53	0.48	0.48	0.48	—
	Tumor	R_TU,0 (nmol·L⁻¹)	5.0	34	17	7	35	16	34^*; 8–80^†
Release rate	Normal tissue	λ_NT,release (min⁻¹·10⁻⁴)	0.47	1.7	0.65	0.60	2.3	1.2	1.2–1.6^‡; 0.5–1.6^*
	Tumor	λ_TU,release (min⁻¹·10⁻⁴)	1.1	3.0	1.7	0	2.1	0	1.2–1.6^‡; 0.4–3.0^*
Volume	Tumor rest^¶	V_{TU,Total,Rest} (L)				0	1.2	0.10	—
Perfusion	Tumor	f_TU, (mL·min⁻¹ ·g⁻¹)	0.10	1.0	0.20	0.015	1.0	0.064	0.01–1^§
Linear binding rate	Serum protein	k_Pr (min⁻¹·10⁻⁴)	2.1	5.6	4.3	10	23	17	—

↵* Data from Kletting et al. (9) obtained using pharmacokinetic model with simpler structure; ¹¹¹In-Octreoscan (dissociation constant = 5.57 nmol/L) data and smaller amounts (5.8 ± 0.4 nmol) of peptide were used.
↵† Calculations based on 80 fmol·10⁻⁶ cells (34) and assumption of 10¹¹ or 10¹² cells L⁻¹ tumor.
↵‡ Derived from half-life (3–4 d) for release of rates of ¹¹¹In (35).
↵¶ Volume of nondelineated, remaining tumor tissue ^§ (36).